Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease by Nesi, G et al.
Accepted Manuscript
Nature-based molecules combined with rivastigmine: A symbiotic approach for the
synthesis of new agents against Alzheimer's disease
Giulia Nesi, Qiuhe Chen, Simona Sestito, Maria Digiacomo, Xiaohong Yang,
Shengnan Wang, Rongbiao Pi, Simona Rapposelli
PII: S0223-5234(17)30798-5
DOI: 10.1016/j.ejmech.2017.10.006
Reference: EJMECH 9798
To appear in: European Journal of Medicinal Chemistry
Received Date: 14 April 2017
Revised Date: 31 July 2017
Accepted Date: 2 October 2017
Please cite this article as: G. Nesi, Q. Chen, S. Sestito, M. Digiacomo, X. Yang, S. Wang, R. Pi, S.
Rapposelli, Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis
of new agents against Alzheimer's disease, European Journal of Medicinal Chemistry (2017), doi:
10.1016/j.ejmech.2017.10.006.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
 
 
 
 
 
 
 
 
 
 
Graphical abstract  
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Nature-based molecules combined with rivastigmine: a symbiotic approach for 
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Wangb, Rongbiao Pib,c,d* and Simona Rapposellia* 
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bDepartment of Pharmacology& Toxicology, School of Pharmaceutical Sciences, Sun Yat-Sen 
University, Guangzhou 5100060(China) 
cInternational Joint Laboratory (SYSU-PolyU HK) of Novel Anti-dementia Drugs of Guangdong, 
Guangzhou 510006, China; 
dGuangdong Province Key Laboratory of Brain Function and Disease, Zhongshan School of 
Medicine, Sun Yat-sen University, Guangzhou 510080, China. 
Abstract 
Starting from nature as original source, new potential agents with pleiotropic activities have been 
synthesized and evaluated as neuroprotective agents. In this work, novel nature-based hybrids, 
combining antioxidant motifs with rivastigmine, have been designed and synthesized. The 
biological results revealed that the new compounds inhibit both AChE and BuChE. In particular, 
lipoic acid hybrids LA1, LA2, LA3 resulted to be the most potent inhibitors of BuChE showing 
IC50 values ranging from 340 to 378 nM. Analogously, all the compounds were able to inhibit the 
self β-amyloid1-42 aggregation. The gallic acid hybrid GA2 as well as the 2-chromonecarboxylic 
acid hybrids CA1 and CA2 prevented the self-mediated Aβ aggregation with percentages of 
inhibition ranging from 53% to 59%.  Finally, some of them also show potent neuroprotective 
effects against glutamate-induced cell death and low toxicity in HT22 cells.   
Keywords: Rivastigmine, Gallic acid, Lipoic acid,  neuroprotective agents, Multifunctional agents, 
Alzheimer's disease 
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1. Introduction 
Alzheimer's disease (AD) represents the most common form of neurodegenerative dementia. 
“Dementia” describes a set of symptoms including memory loss and difficulties in thinking, 
problem-solving or language. Several molecular events have been implicated in the complex AD 
pathophysiology; therefore, to date, many therapeutic strategies are available [1]. Unfortunately, 
only a few treatments have been proved to be able to reduce AD symptoms, but none of them result 
able to halt the disease progression [2], thus the search for new potential drugs is still strongly 
pursued.  
The hallmarks of AD, such as Aβ deposition in senile plaques and neurofibrillary tangles (NFT), are 
strongly intertwined with the production of reactive oxygen species (ROS) and with the onset of 
oxidative stress (OS), which are both considered as the common effectors of the neurodegenerative 
cascade [3]. Several studies reported an increase of OS markers, such as DNA, RNA, lipid and 
protein oxidation, and a simultaneous decrease of the level of antioxidants or detoxifying enzymes 
in patients with AD [4, 5]. Although the specific mechanisms behind the altered redox balance are 
not entirely clear, researchers demonstrated that OS contributes to the Aβ aggregation and to 
phosphorylation of tau protein, thus constituting a trigger event in AD pathogenesis [6, 7]. 
Recently, Zhao et al. reported that amyloid deposition and neurofibrillary tangles improve the levels 
of oxidative stress markers inducing an apparent vicious circle of AD-pathogenesis [8], thus 
confirming the key role played by OS in the AD onset and progression.  
In this context, supported by numerous in vitro and in vivo studies on animal models of AD, natural 
antioxidants could be considered as promising therapeutic tools for design new therapeutic agents 
for AD [9, 10]. Many studies revealed that nature-based antioxidants, such as polyphenols, have 
pleiotropic activity including antioxidant, neuroprotective and anti-Aβ aggregating properties. In 
particular, polyphenols showed to reduce cognitive impairments and Aβ aggregation [11]. 
Nevertheless, while in animal models the antioxidant agents proved to be very effective, human trial 
results are still disappointing. 
In last decade, the multitarget-directed-ligand (MTDL) strategy has become a rich source of 
inspiration for many researchers, thus representing the main rational and successful approach to 
apply in the search of new agents for the treatment of diseases with a complex ethiopathology (e.g. 
neurodegenerative, cardiovascular diseases, and cancers). Many multitarget strategies have been 
developed with the aim to improve the bioavailability of antioxidants in order to promote the direct 
targeting in the brain [12], but also to reduce the possible side effects of native molecules [13]. For 
these reasons, many multifunctional compounds containing antioxidant compounds have been 
rationally designed [14, 15]. 
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In this scenario, in last few years, we investigated some hybrid compounds obtained by the 
conjugation of cholinesterase inhibitors (ChEi), such as tacrine or rivastigmine, with well-known 
antioxidant molecules, such as caffeic acid and ferulic acid [15-18]. These compounds showed 
balanced properties of AChE inhibitor, free radical scavenger, inhibitor of both self- and AChE-
induced Aβ-aggregation, as well as potent neuroprotective effects against H2O2- and glutamate- 
induced cell injury, with low toxicity in HT22 cells.  
The positive results obtained encouraged us to further explore the nature-based compounds (e.g. 
traditional medicines) which could be appropriately combined with AChE-inhibitors. In particular, 
herein we describe the design and synthesis of new molecules obtained by the symbiotic 
combination of rivastigmine with antioxidant agents such as gallic acid (GA), lipoic acid (LA) and 
2-chromonecarboxylic acid (CCA). Synthesized compounds were then investigated in vitro to 
evaluate both AChE and BuChE inhibition, ROS scavengers and Aβ aggregation. In addition, the 
capability to cross the BBB, the toxicity, as well as the neuroprotective activity against glutamate-
induced cytotoxicity, have also been assessed in HT22 cell lines. 
 
Figure 1. Multitarget-directed-ligand (MTDL) approach for new multifunctional antioxidant 
hybrids. 
2. Results and discussion 
2.1. Chemistry 
Scheme 1 reports the general synthetic procedure followed for the synthesis of final compounds. 
Briefly, the amines 1-3 previously described [19], were obtained by two sequential reactions 
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between the appropriate phenol and the N-ethyl-methyl carbamoyl chloride in the presence of Et3N, 
followed by a catalytic reduction of the appropriate N-ethyl-methylcarbamate. 
Subsequently, the condensation of 1-3 with gallic acid in the presence of dicyclohexyl carbodiimide 
(DCC) as a condensing reagent, yielded the final compounds GA1-3. The compounds LA1-3 were 
prepared by the reaction of lipoic chloride, freshly prepared by treatment of lipoic acid with SOCl2, 
and the amine-derivatives 1-3 in the presence of Et3N. Finally, the condensation between the amines 
1-3 and the 4-oxo-4H-1-benzopyran-2-carboxylic acid in the presence of (benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and Et3N gave the compounds 
CA1-3, in modest yields (lower than 50%). 
 
Scheme 1. Synthesis of final compounds. Reagents and conditions: a) Gallic acid, CH2Cl2/DMF, DCC, 
DMAP, r.t., 12h; b) i) Lipoic acid, SOCl2, DCM, 0°C, 4 h; (ii) TEA, DCM/DMF, 0°C, 4h; c) 4-Oxo-4H-1-
benzopyran-2-carboxylic acid, BOP, TEA, r.t., 12h. 
2.2 Biological evaluation 
Cholinergic neurotransmission damage is believed to be one of the major causes of memory 
impairment associated with AD [20]. A recent study performed by Norberg et al. [21] showed that, 
during the progression of AD, the levels of AChE decrease while BuChE levels are likely to 
increase. This compensatory role of BuChE in response to the decrease of AChE activity [22] could 
explain, at least in part, the efficacy proven by rivastigmine (BuChE inhibitor) in clinical trials. 
Consistently, the new synthesized compounds, were firstly tested for their inhibitory activity against 
both AChE and BuChE, using Donepezil and rivastigmine as positive drugs. The data are 
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summarized in Table 1. All the GA-compounds GA1, GA2, GA3 and the CA-derivatives CA1, 
CA2, CA3 elicited a slight affinity against AChE, even if they resulted to be more active than the 
native drug rivastigmine. Moreover, all the compounds showed to inhibit BuChE with a significant 
% of inhibition values and many of them revealed to be more active than the positive drugs. In 
particular, lipoic acid hybrids LA1, LA2, LA3 resulted to be 9-fold more active than donepezil and 
2-fold more active than rivastigmine. Analogously, also the CA-derivatives and the GA3 compound 
exerted a good inhibition against BuChE. Therefore, we further detected the IC50 for the most 
promising compounds for BuChE. As showed in Table 1, LA1-3 showed the best IC50 ranging from 
340 and 378 nM. 
 
Table 1. Percentage inhibition values of ChEs and Aβ1-42 self-induced aggregation, DPPH radical 
scavenging activities (IC50, µM) and BBB Prediction. 
Compd 
% inhibition of 
AChE   (%) ± 
SEMa 
% inhibition 
of BuChE  
(%) ± SEMa 
IC50 of 
BuchE 
(nM) 
Inhibition of Aβ 
self-aggregation 
(%)b 
 
DPPH      radical  
scavenging 
activities  
(IC50, µM)d 
Permeability in 
PAMPA-BBB assaye 
 500nM 500nM Pe             (x10-6cm s-1) Prediction 
GA1 23.56±0.2 7.98±0.4 Nd 47.34±0.1 10.62±0.5 3.08±0.1 CNS+/- 
GA2 5.53±3.2 2.39±0.4 Nd 51.83±1.3 12.88±0.1 4.86±0.1 CNS+ 
GA3 3.48±0.1 58.84±0.0 452±121 27.11±1.3 11.65±0.4 5.14±0.0 CNS+ 
LA1 0.51±0.8 77.43±1.1 356±79 46.28±1.4 4.53±0.2 10.32±1.0 CNS+ 
LA2 3.66±1.3 77.31±0.0 378±133 51.77±6.6 4.30±0.1 27.79±1.3 CNS+ 
LA3 -1.48±0.2 76.68±0.7 340±130 49.84±0.0 4.88±1.0 12.12±0.3 CNS+ 
CA1 9.03±1.0 53.77±0.8 507±179 63.79±7.1 >100µM Nd Nd 
CA2 12.71±0.4 37.11±2.4 650±210 55.23±3.9 >100µM Nd Nd 
CA3 22.08±0.6 49.07±2.7 511±157 67.36±0.9 >100µM Nd Nd 
Rivastigmine 1.92±0.8 30.08±0.1 678±230   16.32±0.3 CNS+ 
Donepezil 90.55±0.5 8.21±1.7 Nd   
  
Curcuminc     51.77 ± 3.33  
  
Trolox       23.49±0.1 
  
aSEM: Standard Error of the mean. b Inhibition of self-mediated Aβ1–42 aggregation. The thioflavin-T fluorescence method was used, and the 
measurements were carried out in the presence of 10 µM inhibitor. c % of inhibition for Curcumin (positive drug) (20µM)  reported by W. Luo et 
al.[23]. dIC50 was defined as the concentration resulting in 50% scavenging activity. eRange of Permeability of PAMPA-BBB Assays (Pe, 10-6 cm s-
1)[24]: Compounds of high BBB permeation (CNS+) Pe>4.7; Compounds of uncertain BBB permeation (CNS+/-) 4.7>Pe>1.8; Compounds of low 
BBB permeation (CNS-) Pe<1.8. nd = not determined. 
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Since many evidence suggested that polyphenols inhibit the Aβ self-aggregation, we performed a 
Thioflavin-T fluorescence assay to evaluate the influence of the tested compounds on amyloid 
fibrils. The measurements were carried out in the presence of 10µM of tested compounds using 
curcumin as reference drugs. Curcumin, a natural polyphenolic molecule originally isolated from 
turmeric, has been shown to block aggregation and fibril formation[25]. The results collected (Table 
1) showed that all the compounds were able to inhibit the Aβ aggregation. In particular the gallic 
acid hybrids GA2 as well as the 2-chromonecarboxylic acid hybrids CA1 and CA2 prevented the 
self-mediated Aβ aggregation with percentages of inhibition ranging from 53% to 59%, which were 
comparable to curcumin (51%) (Table1). Compound CA3 exhibited the highest inhibitory activity 
of 66.44% at 10µM.  
On the basis of the encouraging results, we then decided to test also the radical scavenging 
properties of the synthesised compounds in order to evaluate if the combination of antioxidant 
motifs with the native drug rivastigmine could affect the antioxidant properties. The evaluation was 
performed by using 1,1-diphenyl-2-picryl-hydrazyl (DPPH) assay, with trolox as reference 
compound. As expected, the analysis of the results clearly showed that the GA- and LA- derivatives 
proved to be good scavengers with IC50 values ranging from 4.30 (LA2) to 12.88 (GA2). On the 
contrary, none of CCA hybrids (CA1, CA2, CA3) exhibit significant antioxidant activities.  
The new hybrid compounds were also subjected to an additional assay to evaluate the chelating 
properties. The complexation ability of the new compounds towards Cu2+ was studied by UV–vis 
spectroscopy and the most interesting results were illustrated in Figure 2. The GA-hybrids induced 
the most marked isosbestic shift of the maximum absorption upon the addition of CuCl2, suggesting 
that compounds GA1-3 form a complex with Cu2+. Similarly, also derivatives LA1 and LA2 were 
able to induce a moderate isosbestic shift while the other new synthesized compounds resulted to be 
inactive (data not shown). 
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Figure 2.The copper chelating activity of compounds. UV spectra of compounds (10 µM) alone 
(green line), treated with CuCl2 (10 µM) (red line), and treated with CuCl2 (20 µM) (blue line). 
 
We then performed a preliminary evaluation on HT22 cell viability in order to evaluate the 
cytotoxicity of the new molecules using the colorimetric MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide] assay (Figure 3). No cytotoxic effects were observed for gallic 
acid derivative GA2 and for lipoic acid hybrids LA1, LA2, LA3 at 30, 50 and 100µM 
concentrations whereas analogues GA1 and GA3 appeared to be cytotoxic only at the highest 
concentrations (100 µM). On the contrary CCA-derivatives showed to be cytotoxic, in particular 
CA2 induced a cytotoxic effect at the lowest concentration (30 µM).  
 
Figure 3. Cell toxicity of tested compounds on HT22 cells. Cells were treated with tested 
compounds for 24h, then cell viability was determined using the MTT assay (n = 3). *P < 0.05 
versus control; ***P < 0.001 versus control. 
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The neuroprotective effects of the new molecules were tested in HT22 cell against glutamate-
induced neuronal death, at different concentrations (3, 10 and 30 µM). As reported in Figure 4, 
compounds GA1 and CA2 produced a significant neuroprotection at 10 µM while compound GA2 
displayed an appreciable neuroprotective effect only at the higher concentration (30µM). 
Derivatives GA3, CA1, CA3, LA1, LA2 and LA3 resulted to be inactive in this model of 
neurotoxicity. 
 
Figure 4. Neuroprotective effects of tested compounds on HT22 cells. After pretreated with tested 
compounds for 30 min, cell were incubated with 2 µM glutamate for 24 h. Cell viability was 
determined using the MTT assay (n = 3). ***P< 0.001 versus control; ###P< 0.001 versus glutamate-
treated group. 
For the most active compounds described herein we performed a PAMPA-BBB assay to evaluate 
the ability of the compounds to cross the BBB. This method developed by Di et al.[26] is capable of 
measuring the permeability by passive diffusion of small molecules through an artificial lipid 
membrane. This assay allowed us to classify each hybrids as BBB permeable (CNS+) or BBB 
impermeable (CNS-). Results indicated that gallic acid derivatives GA2, GA3 and lipoic hybrids 
LA1, LA2 and LA3 possessed a high capability to penetrate into the brain (value from 4.86±0.1 for 
GA2 to 27.79±1.3 for LA2) while GA1 showed a slight BBB permeation ability (3.08±0.1). 
3. Conclusion 
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It is increasingly accepted that Aβ deposition in the brain as well as the production of reactive 
oxygen species (ROS) and the onset of oxidative stress (OS) are all important features in 
Alzheimer's disease (AD). Recently, a great number of studies on multi-target ligands have been 
published [27-29]. In the present study, we performed the design and synthesis of new molecules 
obtained by the symbiotic combination of rivastigmine skeleton with natural antioxidant agents 
such as gallic acid (GA), lipoic acid (LA) and 2-chromonecarboxylic acid (CCA).The results 
discussed here show that this strategy has allowed us to obtain new compounds with pleiotropic 
activities that could provide a useful starting point to combine the anti-oxidants and anti-
aggregating properties of nature-based agents with the anticholinesterase activity of drugs that are 
currently used as unique therapeutic tools to treat AD. Interestingly, GA2 derivative revealed to be 
an effective neuroprotective agent in in vitro glutamate-induced neurotoxicity model  with a high % 
of inhibition of Ab aggregation and an appreciable scavengers properties, even if it results to be 
avoid of ChE inhibitory activity. On the contrary, the lipoic acid hybrid compounds LA1-3 show to 
be the most interesting derivatives with pleiotropic activities. Consequently, further investigations 
in different in vitro models will be of help in elucidating the importance of their multitarget profile 
in neuroprotection. 
4. EXPERIMENTAL SECTION 
4.1 Synthesis and characterization 
Melting points were determined on a Kofler hot-stage apparatus and are uncorrected. 1H NMR and 
13C NMR spectra of all compounds were obtained with a a Bruker Advance 400 spectrometer at 400 
MHz in a ~2% solution of CDCl3, CD3OD-d4. Data for 1H NMR spectra are reported as follows: 
chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are reported 
as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, or 
combinations thereof. Chemical shifts (δ) are reported in parts per million (ppm) downfield from 
tetramethylsilane and referenced from solvent references. ATR-FTIR experiments were conducted 
using a Ftir agilent 620 spectrometer equipment with a DLaTGS detector. Spectra were the result of 
32 scans with the resolution 4 cm-1 in the spectral range of 4000-500 cm-1. The 95% purity of tested 
compounds was confirmed by combustion analysis. Chromatographic separation was performed on 
silica gel columns by flash (Kieselgel 40, 0.040–0.063 mm; Merck). Merck gel plates (60 F254) 
were used for analytical TLC. UV light was used to examine the spots.  Evaporation was performed 
in vacuo (rotating evaporator). Sodium sulfate was always used as the drying agent. Commercially 
available chemicals were purchased from Sigma-Aldrich. 
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4.1.1 General procedure for synthesis of compounds GA1-3  
To a solution of gallic acid (116 mg, 0.68 mmoli) in THF (2 mL) was added dropwise a solution of 
appropriate amine 1-3  (0.68 mmoli) and N,N′-Dicyclohexylcarbodiimide (DCC) (62.1 mg, 0.68 
mmol) in THF (2 mL). The mixture was stirred 7 h at r.t., then, the organic layer was dried and 
concentrated. 
4.1.1.1. 3-(3,4,5-trihydroxybenzamido)phenyl-ethyl(methyl)carbamate GA1. Compound GA1 was 
synthesized from 3-aminophenyl-ethyl(methyl)carbamate 1 (132 mg, 0.68 mmol). The crude 
product was purified by flash chromatography using n-Hexane/AcOEt (90:10) as the eluent to give 
compound GA1(94 mg, 0.27 mmol, 40 % yield) as a yellow oil; IR: 3305 υ (O-H of phenol), 1598 δ 
(N-H of amide) cm-1. 1H NMR (CD3OD-d4) δ: 1.18 (t, 1.5 H, J = 6.8 Hz, Me, rotamer); 1.25 (t, 1.5 
H, J = 6.8 Hz, Me, rotamer); 2.98 (s, 1.5 H, Me, rotamer); 3.10 (s, 1.5 H, Me, rotamer); 3.39 (q, 1 
H, J = 6.8 Hz, CH2, rotamer); 3.51 (q, 1 H, J = 6.8 Hz, CH2, rotamer); 6.85 (d, 1 H, J = 7.2 Hz, Ar); 
6.95 (s, 2 H, Ar); 7.30-7.34 (m, 1 H, Ar); 7.47 (d, 1H, J = 8.4 Hz, Ar); 7.54 (s, 1H, Ar) ppm. 13C 
NMR (CD3OD-d4) δ: 169.1, 156.3, 153.0, 146.7, 141.2, 138.6, 130.2, 126.5, 118.7, 118.4, 115.5, 
108.2, 45.1, 34.5 (rotamer), 34.3 (rotamer), 13.4 (rotamer), 12.6 (rotamer) ppm. Anal. (C17H18N2O6) 
C, H, N % Calcd: 58.96 (C), 5.24 (H), 8.09 (N). % Found: 59.03 (C), 5.09 (H), 8.36 (N).  
4.1.1.2 3-((3,4,5-trihydroxybenzamido)methyl)phenyl-ethyl(methyl)carbamate GA2. Compound 
GA2 was synthesized from 3-(aminomethyl)phenyl-ethyl(methyl)carbamate 2 (142 mg, 0.68 
mmol). The crude product was purified by flash chromatography using n-Hexane/AcOEt (90:10) as 
the eluent to give compound GA1 (112 mg, 0.31 mmol, 45 % yield) as a yellow oil; IR: 3341 υ (O-
H of phenol), 1572 δ (N-H of amide) cm-1. 1H NMR (CD3OD-d4) δ: 1.18 (t, 1.5 H, J = 7.0 Hz, Me, 
rotamer); 1.25 (t, 1.5 H, J =7.0 Hz, Me, rotamer); 2.97 (s, 1.5 H, Me, rotamer); 3.09 (s, 1.5 H, Me, 
rotamer); 3.38 (q, 1 H, J = 7.0 Hz, CH2, rotamer); 3.47 (q, 1 H, J = 7.0 Hz, CH2, rotamer); 4.52 (s, 2 
H, CH2NH2); 6.88 (s, 2 H, Ar); 6.99 (d, 1 H, J = 7.2 Hz, Ar); 7.07 (s, 1 H, Ar); 7.20 (d, 1 H, J = 7.6 
Hz, Ar); 7.32-7.36 (m, 1 H, Ar) ppm. 13C NMR (CD3OD-d4) δ: 170.5, 156.4, 152.9, 146.8, 142.2, 
138.7, 130.4, 125.6, 125.5, 121.9, 121.5, 107.8, 45.1, 44.0,  34.5 (rotamer), 34.3 (rotamer), 13.4 
(rotamer), 12.6 (rotamer) ppm. Anal. (C18H20N2O6) C, H, N % Calcd: 59.99 (C), 5.59 (H), 7.77 (N). 
% Found: 60.13 (C), 5.48 (H), 7.95 (N). 
4.1.1.3 3-(2-(3,4,5-trihydroxybenzamido)ethyl)phenyl-ethyl(methyl)carbamate GA3. Compound 
GA3 was synthesized from 3-(2-aminoethyl)phenyl-ethyl(methyl)carbamate 3 (131mg, 0.68 mmol). 
The crude product was purified by flash chromatography using n-Hexane/AcOEt/MeOH 
(90:10:0.4) as the eluent to give compound GA3 (107 mg, 0.29 mmol, 42 % yield) as a yellow oil; 
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IR: 3325 υ (O-H of phenol), 1607 δ (N-H of amide) cm-1.  1H NMR (CD3OD-d4) δ: 1.17 (t, 1.5 H, J 
= 7.2 Hz, Me, rotamer); 1.24 (t, 1.5 H, J = 7.2 Hz, Me, rotamer); 2.89 (t, 2 H, J = 6.4 Hz, CH2); 
2.97 (s, 1.5 H, Me, rotamer); 3.05 (t, 2 H, J = 6.4 Hz, CH2); 3.09 (s, 1.5 H, Me, rotamer); 3.44 (q, 1 
H, J = 7.2 Hz, CH2, rotamer); 3.52 (q, 1 H, J = 7.2 Hz, CH2, rotamer); 6.95 (d, 1 H, J = 8.4 Hz, Ar); 
6.99 (s, 1 H, Ar) 7.06 (s, 2 H, Ar); 7.08 (d, 1 H, J = 7.6 Hz, Ar); 7.28-7.32 (m, 1 H, Ar) ppm. 13C 
NMR (CD3OD-d4) δ: 171.1, 156.4, 153.0, 146.3, 142.0, 139.2, 130.5, 127.0, 123.4, 123.0, 120.9, 
110.2, 56.1, 45.2, 34.5 (rotamer), 34.3 (rotamer), 33.0, 13.4 (rotamer), 12.6 (rotamer) ppm. Anal. 
(C19H22N2O6) C, H, N % Calcd: 60.95 (C), 5.92 (H), 7.48 (N). % Found: 61.10 (C), 6.21 (H), 7.33 
(N). 
4.1.2 General procedure for synthesis of compounds LA1-3 
A suspension of lipoic acid (128 mg, 0.62 mmol) in DCM (3.0 mL), under N2 atmosphere, was 
cooled to 0 °C and treated with thionyl chloride (0.07 mL, 0.99 mmol). The mixture was stirred at 0 
°C for 4 h, then the solvent was removed under reduced pressure to give the acid chloride as a 
yellow solid. A solution of the acid chloride in DCM (2.0 mL) was added to a solution of the 
appropriate amine 1-3 (0.52 mmol) and Et3N (0.07 mL, 0.52 mmol) in DCM (2.0 mL), cooled to 0 
°C. The mixture was stirred at 0 °C for 4 h, diluted with DCM and washed with saturated aqueous 
NaHCO3. The organic phase was dried over Na2SO4 and the solvent evaporated. 
4.1.2.1. 3-{[5-(1,2-dithiolan-3-yl)pentanoyl]amino}phenyl-ethyl(methyl)carbamate LA1. 
Compound LA1 was synthesized from 3-aminophenyl-ethyl(methyl)carbamate 1 (100 mg, 0.52 
mmol). The crude product was purified by flash chromatography using CHCl3/MeOH (98:2) as the 
eluent to give compound LA1 (86 mg, 0.26 mmol, 50 % yield) as a yellow oil; 1H NMR (CDCl3) δ: 
1.19 (t, 1.5 H, J = 7.0 Hz, Me, rotamer), 1.24 (t, 1.5 H, J = 7.0 Hz, Me, rotamer), 1.41-1.52 (m, 2 H, 
CH2), 1.61–1.74 (m, 4 H, CH2), 1.86–1.94 (m, 1 H, CH2), 2.21 (t, 2 H, J = 7.2 Hz, CH2), 2.41–2.49 
(m, 1 H, CH2), 2.99 (s, 1.5 H, Me, rotamer), 3.06 (s, 1.5 H, Me, rotamer), 3.07–3.20 (m, 2 H, CH2), 
3.38–3.49 (m, 2 H, CH2), 3.53-3.60 (m, 1 H, CH), 6.76 (d, 1 H, J = 7.6 Hz, Ar), 7.00-7.04 (m, 1 H, 
Ar), 7.14-7.18 (m, 1 H, Ar), 7.43 (s, 1 H, Ar), 7.96 (br d, 1 H, J = 6.4 Hz, NH) ppm. 13C NMR 
(CDCl3) δ: 171.4, 155.1, 155.0, 151.6, 139.5, 129.2, 116.9, 114.1, 56.5, 44.3, 40.3, 38.6, 37.0, 34.8, 
34.4 (CH2, rotamer), 34.0 (CH2, rotamer), 29.0, 25.2, 13.3 (CH3, rotamer), 12.6 (CH3, rotamer) 
ppm. Anal. (C18H26N2O3S2) C, H, N, S % Calcd: 56.51 (C), 6.85 (H), 7.32 (N), 16.76 (S). % Found: 
56.23 (C), 7.09 (H), 7.36 (N), 16.89 (S).  
4.1.2.2. 3-({[5-(1,2-dithiolan-3-yl)pentanoyl]amino}methyl)phenyl-ethyl(methyl)carbamate LA2. 
Compound LA2 was synthesized from 3-(aminomethyl)phenyl-ethyl(methyl)carbamate 2 (108 mg, 
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0.52 mmol). The crude product was purified by flash chromatography using CHCl3/MeOH (98:2) to 
give compound LA2 (88.0 mg, 0.25 mmol, 49 % yield) as a yellow oil; 1H NMR (CDCl3) δ: 1.17 (t, 
1.5 H, J = 7.0 Hz, Me, rotamer), 1.22 (t, 1.5 H, J = 7.0 Hz, Me, rotamer), 1.39–1.51 (m, 2 H, CH2), 
1.60–1.72 (m, 4 H, CH2), 1.84–1.91 (m, 1 H, CH2), 2.19 (t, 2 H, J = 7.4 Hz, CH2), 2.39– 2.47 (m, 1 
H, CH2), 2.96 (s, 1.5 H, Me, rotamer), 3.05 (s, 1.5 H, Me, rotamer), 3.07–3.19 (m, 2 H, CH2), 3.38 
(q, 1 H, J = 7.0 Hz, CH2, rotamer), 3.45 (q, 1 H, J = 7.0 Hz, CH2, rotamer), 3.51–3.58 (m, 1 H, CH), 
4.37 (d, 2 H, J = 5.6 Hz, CH2NH), 6.02 (br s, 1 H, NH), 6.97-7.03 (m, 2 H, Ar), 7.07 (d, 1 H, J = 7.6 
Hz, Ar), 7.26–7.3 (m, 1 H, Ar) ppm. 13C NMR (CDCl3) δ: 172.7, 154.5, 151.9, 139.8, 129.7, 124.8, 
121.4, 121.1, 56.5, 44.3, 43.5, 40.4, 38.6, 36.6, 34.8, 34.4 (CH2, rotamer), 34.0 (CH2 , rotamer), 
29.0, 25.5, 13.4 (Me, rotamer), 12.6 (Me, rotamer) ppm. Anal. (C19H28N2O3S2) C, H, N, S % Calcd: 
57.54 (C), 7.12 (H), 7.06 (N), 16.17 (S). % Found: 57.23 (C), 7.31 (H), 7.20 (N), 16.33 (S).  
4.1.2.3. 3-(2-{[5-(1,2-dithiolan-3-yl)pentanoyl]amino}ethyl)phenyl-ethyl(methyl)carbamate LA3. 
Compound LA3 was synthesized from 3-(2-aminoethyl)phenyl-ethyl(methyl)carbamate 3 (94.0 mg, 
0.52 mmol). The crude product was purified by flash chromatography using CHCl3/MeOH (98:2) to 
give compound LA3 (110 mg, 0.27 mmol, 52 % yield) as a pale yellow oil; 1H NMR (CDCl3) δ: 
1.18 (t, 1.5 H, J = 7.2 Hz, Me, rotamer), 1.23 (t, 1.5 H, J = 7.2 Hz, Me, rotamer), 1.41-1.45 (m, 2H, 
CH2), 1.60-1.68 (m, 4H, CH2), 1.88-1.91 (m, 1H, CH2), 2.13 (t, 2H, J = 7.6 Hz, CH2), 2.40-2.49 (m, 
1H, CH2), 2.80 (t, 2H, J = 6.8 Hz, CH2), 2.98 (s, 1.5 H, Me, rotamer), 3.06 (s, 1.5 H, Me, rotamer), 
3.09-3.19 (m, 2H, CH2), 3.39-3.59 (m, 5H, CH, CH2), 6.94-7.01 (m, 3H, Ar), 7.26-7.30 (m, 1H, Ar) 
ppm. 13C NMR(CDCl3) δ: 173.0, 151.8, 140.5, 129.4, 129.6, 125.8, 122.5, 120.0, 56.6, 44.3, 40.4 
(CH2, rotamer), 40.4 (CH2, rotamer), 38.6, 36.5, 35.6, 34.8 (Me, rotamer), 34.4 (Me, rotamer), 34.0, 
29.8, 29.0, 13.4, 12.7 ppm. Anal. (C20H30N2O3S2) C, H, N % Calcd: 58.50 (C), 7.36 (H), 6.82 (N), 
15.62 (S). % Found: 58.77 (C), 7.45 (H), 6.92 (N), 15.81 (S). 
4.1.3. General procedure for synthesis of compounds CA1-3 
To a stirred solution of  Chromone-2-carboxylic acid (98 mg, 0.51 mmol) and (Benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (296 mg, 0.60 mmol) in DCM (8.0 
mL) were added the appropriate amine 1-3 (100 mg, 0.51 mmol) and then Et3N (0.20 ml). The 
resulting mixture was stirred at r.t. for 12 h, then it was diluted with DCM and washed with a 
solution of HCl 10%, NaHCO3 0.5M and water. The organic layer was dried over Na2SO4 and the 
solvent evaporated. 
4.1.3.1 3-{[(4-oxo-4H-chromen-2-yl)carbonyl]amino}phenyl-ethyl(methyl)carbamate CA1. 
Compound CA1 was synthesized from 3-aminophenyl-ethyl(methyl)carbamate 1 (70 mg, 0.31 
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mmol). The crude product was purified by flash chromatography using CHCl3/MeOH (98:2) as the 
eluent to give compound CA1(53 mg, 0.15 mmol, 47 % yield) as a white solid; m.p. 155-160 °C.1H 
NMR (CDCl3) δ: 1.19-1.27 (m, 3 H, Me); 3.01 (s, 1.5 H, Me, rotamer); 3.08 (s, 1.5 H, Me, 
rotamer); 3.40-3.52 (m, 2H, CH2); 6.94-6.98 (m, 1 H, Ar); 7.37 (dd, 1H, J = 8.4, 8.0 Hz, Ar); 7.48-
7.54 (m, 2H, Ar); 7.59-7.62 (m, 2 H, Ar); 7.79 (dd, 1H, J = 8.0, 7.6 Hz, Ar); 8.25 (d, 1H, J = 8.0 
Hz, Ar); 8.63 (s, 1H, Ar) ppm. 13C NMR (CDCl3) δ: 178.1; 157.1; 155.3; 154.5; 152.2; 137.2; 
134.9; 130.0; 126.4; 126.3; 124.5; 119.1; 119.0; 118.2; 117.3; 114.4; 112.9; 44.3; 34.4 (rotamer); 
34.00 (rotamer); 13.4 (rotamer); 12.6 (rotamer) ppm. Anal. (C20H18N2O5) C, H, N % Calcd: 65.57 
(C), 4.95 (H), 7.65 (N). % Found: 65.79 (C), 4.98 (H), 7.96 (N). 
4.1.3.2 3-({[(4-oxo-4H-chromen-2-yl)carbonyl]amino}methyl)phenyl-ethyl(methyl)carbamate 
CA2. Compound CA2 was synthesized from 3-(aminomethyl)phenyl-ethyl(methyl)carbamate 2 (65 
mg, 0.31 mmol). The crude product was purified by flash chromatography using CHCl3/MeOH 
(95:5) as the eluent to give compound CA2 (41 mg, 0.11 mmol, 35 % yield); m.p. 165-170 °C. 1H 
NMR (CDCl3) δ: 1.17–1.26 (m, 3 H, Me); 2.98 (s, 1.5 H, Me, rotamer); 3.06 (s, 1.5 H, Me, 
rotamer); 3.41 (q, 1H, J = 6.8 Hz, CH2, rotamer); 3.47 (q, 1H, J = 6.8 Hz, CH2, rotamer); 4.65 (d, 
2H, J = 6.0 Hz, CH2); 7.05-7.10 (m, 1H, Ar); 7.11-7.14 (m, 1H, Ar); 7.20-7.22 (m, 2H, Ar); 7.37 (t, 
1H, J = 8.0 Hz, Ar); 7.43-7.47 (m, 1H, Ar); 7.52 (d, 1H, J = 8.0 Hz, Ar); 7.70-7.74 (m, 1H, Ar); 
8.22 (dd, 1H, J = 8.0, 1.6 Hz, Ar) ppm. 13C NMR (CDCl3) δ: 178.3; 159.4; 155.4; 154.7; 152.0; 
138.5; 134.7; 129.9; 126.1; 126.1; 125.0; 124.4; 121.7; 121.6; 118.3; 112.5; 44.2; 43.7; 34.4 
(rotamer); 34.0 (rotamer); 13.3 (rotamer); 12.6 (rotamer) ppm. Anal. (C21H20N2O5) C, H, N % 
Calcd: 66.31 (C), 5.30 (H), 7.36 (N). % Found: 66.57 (C), 5.46 (H), 7.39 (N). 
4.1.3.3. 3-({[(4-oxo-4H-chromen-2-yl)carbonyl]amino}ethyl)phenyl-ethyl(methyl)carbamate 
CA3. Compound CA3 was synthesized from 3-(aminoethyl)phenyl-ethyl(methyl)carbamate 3 (69 
mg, 0.31 mmol). The crude product was purified by flash chromatography using CHCl3/MeOH 
(98:2) as the eluent to give compound CA3 (55 mg, 0.14 mmol, 45 % yield) as a white solid; m.p. 
134-139 °C. 1H NMR (CDCl3) δ: 1.13 (t, 1.5H, J = 7.2 Hz, Me, rotamer); 1.21 (t, 1.5H, J = 7.2 Hz, 
Me, rotamer); 2.92-2.95 (m, 2H, CH2); 2.93 (s, 1.5 H, Me, rotamer);  3.04 (s, 1.5 H, Me, rotamer); 
3.33 (q, 1H, J = 7.2 Hz, CH2, rotamer); 3.42 (q, 1H, J = 7.2 Hz, CH2, rotamer); 3.72 (q, 2H, J = 6.8 
Hz, CH2); 7.00-7.02 (m, 2H, Ar); 7.06 (d, 1H, J = 7.6 Hz, Ar); 7.14-7.18 (m, 2H, Ar, NH); 7.31 (dd, 
1H, J = 7.6, 8.0 Hz, Ar); 7.40 (dd, 1H, J = 7.6, 8.0 Hz, Ar);  7.51 (d, 1H, J = 8.4 Hz, Ar); 7.68 (t, 
1H, J = 8.4 Hz, Ar); 8.17 (dd, 1H, J = 7.6, 1.6 Hz, Ar) ppm. 13C NMR (CDCl3) δ: 178.3; 159.4; 
155.4; 154.8; 151.9; 139.9; 134.5; 129.7; 126.0; 126.0; 125.8; 124.4; 122.5; 122.5; 120.3; 118.5; 
112.1; 44.2; 41.0; 35.3; 34.3 (rotamer) 33.9 (rotamer); 13.3 (rotamer); 12.5 (rotamer) ppm. Anal. 
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(C22H22N2O5) C, H, N % Calcd: 66.99 (C), 5.62 (H), 7.10 (N). % Found: 66.82 (C), 5.55 (H), 7.16 
(N). 
Supporting information 
*Experimental procedures covering  the spectral characterization of compounds GA1-3, LA1-3 and 
CA1-3 and the biological methods.  
AUTHOR INFORMATION 
*Corresponding authors: Rongbiao Pi (pirb@mail.sysu.edu.cn) and Simona Rapposelli 
(simona.rapposelli@farm.unipi.it) 
Author contributions: 1 Both authors contributed equally. G.N., S.S. and M.D. synthesized 
the compounds. Q.C., X.Y. and S.W. performed most of the biological work. S.R. and R.P.  
conceived the idea and coordinated the project. G.N. Q.C., S.R. and R.P. wrote the main manuscript 
text. All authors reviewed the manuscript. 
Notes: The authors declare no competing financial interest. 
ACKNOWLEDGMENTS 
This study was supported by Guangdong Provincial International Cooperation Project of Science & 
Technology (No. 2013B051000038), National Natural Science Foundation of China (No. 31371070 
and No. 81671264) and the Fundamental Research Funds for the Central Universities 
(No.15ykjc08b) to R. Pi. The authors also thank the COST action CA15135 (Multitarget Paradigm 
for Innovative Ligand Identification in the Drug Discovery Process MuTaLig) for support. 
ABBREVIATIONS USED 
GA, gallic acid;  LA,  lipoic acid; CCA, 2-chromonecarboxylic acid; HT22, hippocampal neuronal 
cell line; OS, oxidative stress; MTDL, multitarget-directed-ligand; DPPH, 1,1-diphenyl-2-picryl-
hydrazyl; MTT, [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide];  
REFERENCES 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
[1] A. Uflacker, P.M. Doraiswamy, Alzheimer’s Disease: An Overview of Recent Developments 
and a Look to the Future, Focus, 15 (2017) 13-17. 
[2] N.S. Buckholtz, Perspective: in search of biomarkers, Nature, 475 (2011) S8-S8. 
[3] M.P. Mattson, Pathways towards and away from Alzheimer's disease, Nature, 430 (2004) 631-
639. 
[4] W.R. Markesbery, M.A. Lovell, Damage to lipids, proteins, DNA, and RNA in mild cognitive 
impairment, Archives of Neurology, 64 (2007) 954-956. 
[5] L. Minghetti, A. Greco, M. Puopolo, M. Combrinck, D. Warden, A.D. Smith, Peripheral 
reductive capacity is associated with cognitive performance and survival in Alzheimer's disease, 
Journal of neuroinflammation, 3 (2006) 4. 
[6] M. Dumont, M.F. Beal, Neuroprotective strategies involving ROS in Alzheimer disease, Free 
radical biology and medicine, 51 (2011) 1014-1026. 
[7] J. Hroudová, N. Singh, Z. Fišar, K.K. Ghosh, Progress in drug development for Alzheimer's 
disease: an overview in relation to mitochondrial energy metabolism, European journal of medicinal 
chemistry, 121 (2016) 774-784. 
[8] Y. Zhao, B. Zhao, Oxidative stress and the pathogenesis of Alzheimer's disease, Oxidative 
Medicine and Cellular Longevity, 2013 (2013). 
[9] C. Mancuso, T.E. Bates, D.A. Butterfield, S. Calafato, C. Cornelius, A.D. Lorenzo, A.T. 
Dinkova Kostova, V. Calabrese, Natural antioxidants in Alzheimer's disease, Expert opinion on 
investigational drugs, 16 (2007) 1921-1931. 
[10] G. Nesi, S. Sestito, M. Digiacomo, S. Rapposelli, Oxidative Stress, Mitochondrial 
Abnormalities and Proteins Deposition: Multitarget Approaches in Alzheimer's Disease, Curr Top 
Med Chem, (2017). 
[11] C. Ramassamy, Emerging role of polyphenolic compounds in the treatment of 
neurodegenerative diseases: a review of their intracellular targets, European journal of 
pharmacology, 545 (2006) 51-64. 
[12] A. Tewari, V. Mahendru, A. Sinha, F. Bilotta, Antioxidants: The new frontier for translational 
research in cerebroprotection, Journal of Anaesthesiology Clinical Pharmacology, 30 (2014) 160. 
[13] F. Di Domenico, E. Barone, M. Perluigi, D.A. Butterfield, Strategy to reduce free radical 
species in Alzheimer’s disease: an update of selected antioxidants, Expert review of 
neurotherapeutics, 15 (2015) 19-40. 
[14] Y. Bansal, O. Silakari, Multifunctional compounds: Smart molecules for multifactorial 
diseases, European Journal of Medicinal Chemistry, 76 (2014) 31-42. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
[15] R. Pi, X. Mao, X. Chao, Z. Cheng, M. Liu, X. Duan, M. Ye, X. Chen, Z. Mei, P. Liu, Tacrine-
6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-β-mediated Alzheimer's disease-
associated pathogenesis in vitro and in vivo, PLoS One, 7 (2012) e31921. 
[16] X. Chao, X. He, Y. Yang, X. Zhou, M. Jin, S. Liu, Z. Cheng, P. Liu, Y. Wang, J. Yu, Y. Tan, 
Y. Huang, J. Qin, S. Rapposelli, R. Pi, Design, synthesis and pharmacological evaluation of novel 
tacrine–caffeic acid hybrids as multi-targeted compounds against Alzheimer’s disease, Bioorganic 
& Medicinal Chemistry Letters, 22 (2012) 6498-6502. 
[17] M. Digiacomo, Z. Chen, S. Wang, A. Lapucci, M. Macchia, X. Yang, J. Chu, Y. Han, R. Pi, S. 
Rapposelli, Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against 
several disease pathways of AD, Bioorganic and Medicinal Chemistry Letters, 25 (2015) 807-810. 
[18] Z. Chen, M. Digiacomo, Y. Tu, Q. Gu, S. Wang, X. Yang, J. Chu, Q. Chen, Y. Han, J. Chen, 
G. Nesi, S. Sestito, M. Macchia, S. Rapposelli, R. Pi, Discovery of novel rivastigmine-
hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease, European Journal 
of Medicinal Chemistry, 125 (2017) 784-792. 
[19] Z. Chen, M. Digiacomo, Y. Tu, Q. Gu, S. Wang, X. Yang, J. Chu, Q. Chen, Y. Han, J. Chen, 
Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for 
Alzheimer's disease, European Journal of Medicinal Chemistry, 125 (2017) 784-792. 
[20] A. Kulshreshtha, P. Piplani, Current pharmacotherapy and putative disease-modifying therapy 
for Alzheimer's disease, Neurological sciences : official journal of the Italian Neurological Society 
and of the Italian Society of Clinical Neurophysiology, 37 (2016) 1403-1435. 
[21] A. Nordberg, C. Ballard, R. Bullock, T. Darreh-Shori, M. Somogyi, A Review of 
Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimer’s Disease, The 
Primary Care Companion for CNS Disorders, 15 (2013) PCC.12r01412. 
[22] A. Venneri, W.J. McGeown, M.F. Shanks, Empirical evidence of neuroprotection by dual 
cholinesterase inhibition in Alzheimer's disease, Neuroreport, 16 (2005) 107-110. 
[23] W. Luo, Y.-P. Li, Y. He, S.-L. Huang, J.-H. Tan, T.-M. Ou, D. Li, L.-Q. Gu, Z.-S. Huang, 
Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for 
cholinesterases and amyloid beta aggregation, Bioorganic & medicinal chemistry, 19 (2011) 763-
770. 
[24] Z. Wang, Y. Wang, B. Wang, W. Li, L. Huang, X. Li, Design, Synthesis, and Evaluation of 
Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive 
Improvement in a Rat Model of Neurodegeneration in Alzheimer’s Disease, Journal of Medicinal 
Chemistry, 58 (2015) 8616-8637. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
[25] K. Ono, K. Hasegawa, H. Naiki, M. Yamada, Curcumin has potent anti‐amyloidogenic effects 
for Alzheimer's β‐amyloid fibrils in vitro, Journal of neuroscience research, 75 (2004) 742-750. 
[26] L. Di, E.H. Kerns, K. Fan, O.J. McConnell, G.T. Carter, High throughput artificial membrane 
permeability assay for blood–brain barrier, European journal of medicinal chemistry, 38 (2003) 
223-232. 
[27] R.S. Keri, C. Quintanova, S. Chaves, D.F. Silva, S.M. Cardoso, M.A. Santos, New Tacrine 
Hybrids with Natural‐Based Cysteine Derivatives as Multitargeted Drugs for Potential Treatment of 
Alzheimer's Disease, Chemical biology & drug design, 87 (2016) 101-111. 
[28] N. Guzior, A. Wieckowska, D. Panek, B. Malawska, Recent development of multifunctional 
agents as potential drug candidates for the treatment of Alzheimer’s disease, Current medicinal 
chemistry, 22 (2015) 373-404. 
[29] A. Kulshreshtha, P. Piplani, Ameliorative effects of amide derivatives of 1, 3, 4-thiadiazoles on 
scopolamine induced cognitive dysfunction, European journal of medicinal chemistry, 122 (2016) 
557-573. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Highlights 
 
1. A symbiotic combination of rivastigmine skeleton with natural antioxidant agents has been 
performed 
2. The ChEs inhibitory activity as well as the % inhibition of Ab-aggregation were evaluated 
3.  LA2 and CA2 showed high scavenger properties and a good BBB permeability in PAMPA 
assay. 
5. GA1 and CA2 produced a significant neuroprotection at 10 µM 
 
